SynthesisHaematologica2014
A new prognostic score for AIDS-related lymphomas in the rituximab-era.
Synthesis in Haematologica, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 61 citations in OpenAlex.
- Hodgkin and non-Hodgkin lymphomas in the post-antiretroviral therapy era according to HIV virological suppression.HIV medicine · 2026Observational
- HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.Current HIV research · 2026Review
- A promising prognostic model for patients with AIDS-related lymphoma in the combination antiretroviral therapy era.AIDS (London, England) · 2025Article
- Circulating Biomarker Panorama in HIV-Associated Lymphoma: A Bridge from Early Risk Warning to Prognostic Stratification.Biomolecules · 2025Review
- Clinicopathological features and prognostic factors of AIDS-related lymphoma: a retrospective single-center study in China.Annals of hematology · 2025Article
- Primary Effusion Lymphoma Prognostic Score (PEL-PS): A Validated International Prognostic Score in HIV-Associated Primary Effusion Lymphoma.American journal of hematology · 2025Article
- Lymphoma Imaging in HIV and Non-HIV Patients: A Retrospective Cross-Sectional Study With Clinical and Pathological Correlation.Cancer informatics · 2025Article
- Molecular and clinical insights into HIV-associated and HIV-negative aggressive B-cell lymphomas: prognostic quantitative biomarker analysis and therapeutic implications.Frontiers in oncology · 2025Article
- Survival of HIV associated diffuse large B-cell lymphoma and Burkitt lymphoma in China.Scientific reports · 2024Article
- The role of autologous bone marrow transplantation in primary effusion lymphoma: a case report and literature review.Hematology, transfusion and cell therapy · 2024Review
- Still Far to Go With Characterisation of Molecular and Genetic Features of Diffuse Large B-Cell Lymphoma in People Living With HIV: A Scoping Review.Oncology reviews · 2024Article
- Diffuse Large B-Cell Lymphoma in the HIV Setting.Cancers · 2023Review
- A promising prognostic model for predicting survival of patients with HIV-related diffuse large B-cell lymphoma in the cART era.Cancer medicine · 2023Observational
- Clinical characteristics and outcomes of newly diagnosed patients with HIV-associated aggressive B-cell NHL in China.Journal of cellular and molecular medicine · 2022Article
- A Novel Prognostic Score Including the CD4/CD8 for AIDS-Related Lymphoma.Frontiers in cellular and infection microbiology · 2022Article
- Article
- Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation.Journal of cancer research and clinical oncology · 2021Article
- Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Real-world outcomes of AIDS-related Burkitt lymphoma: a retrospective study of 78 cases over a 10-year period.International journal of hematology · 2021Article
- The Changing Landscape of Lymphoma Associated with HIV Infection.Current oncology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 9 institutions in 4 countries.
Funding
Abstract
While the International Prognostic Index is commonly used to predict outcomes in immunocompetent patients with aggressive B-cell non-Hodgkin lymphomas, HIV-infection is an important competing risk for death in patients with AIDS-related lymphomas. We investigated whether a newly created prognostic score (AIDS-related lymphoma International Prognostic Index) could better assess risk of death in patients with AIDS-related lymphomas. We randomly divided a dataset of 487 patients newly diagnosed with AIDS-related lymphomas and treated with rituximab-containing chemoimmunotherapy into a training (n=244) and validation (n=243) set. We examined the association of HIV-related and other known risk factors with overall survival in both sets independently. We defined a new score (AIDS-related lymphoma International Prognostic Index) by assigning weights to each significant predictor [age-adjusted International Prognostic Index, extranodal sites, HIV-score (composed of CD4 count, viral load, and prior history of AIDS)] with three risk categories similar to the age-adjusted International Prognostic Index (low, intermediate and high risk). We compared the prognostic value for overall survival between AIDS-related lymphoma International Prognostic Index and age-adjusted International Prognostic Index in the validation set and found that the AIDS-related lymphoma International Prognostic Index performed significantly better in predicting risk of death than the age-adjusted International Prognostic Index (P=0.004) and better discriminated risk of death between each risk category (P=0.015 vs. P=0.13). Twenty-eight percent of patients were defined as low risk by the ARL-IPI and had an estimated 5-year overall survival (OS) of 78% (52% intermediate risk, 5-year OS 60%; 20% high risk, 5-year OS 50%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.